Lena Lenhammar
Research Engineer at Department of Medical Sciences; Cancer Pharmacology and Computational Medicine
- Telephone:
- +46 18 611 49 30
- E-mail:
- Lena.Lenhammar@medsci.uu.se
- Visiting address:
- Akademiska sjukhuset, ingång 61
- Postal address:
- Akademiska sjukhuset, ingång 61
751 85 Uppsala
Publications
Recent publications
-
Part of BMC Pharmacology & Toxicology, 2024
- DOI for Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Download full text (pdf) of Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
-
Part of BMC Cancer, 2023
- DOI for Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Download full text (pdf) of Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
-
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Scientific Reports, 2020
- DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
-
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Part of BMC Research Notes, 2019
- DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
- Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
-
Part of Bioorganic & Medicinal Chemistry, p. 897-911, 2017
- DOI for Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
- Download full text (pdf) of Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
All publications
Articles in journal
-
Part of BMC Pharmacology & Toxicology, 2024
- DOI for Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Download full text (pdf) of Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
-
Part of BMC Cancer, 2023
- DOI for Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Download full text (pdf) of Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
-
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Scientific Reports, 2020
- DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
-
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Part of BMC Research Notes, 2019
- DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
- Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
-
Part of Bioorganic & Medicinal Chemistry, p. 897-911, 2017
- DOI for Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
- Download full text (pdf) of Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
-
Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017